Theranostics in Neuroendocrine Tumors: Updates and Emerging Technologies.

Advancements in somatostatin receptor (SSTR) targeted imaging and treatment of well-differentiated neuroendocrine tumors (NETs) have revolutionized the management of these tumors. This comprehensive review delves into the current practice, discussing the use of the various FDA-approved SSTR-agonist PET tracers and the predictive imaging biomarkers, and elaborating on Lu177-DOTATATE peptide receptor radionuclide therapy (PRRT) including the evolving areas of post-therapy imaging practices, PRRT retreatment, and the potential role of dosimetry in optimizing patient treatments. The future directions sections highlight ongoing research on investigational PET imaging radiotracers, future prospects in alpha particle therapy, and combination therapy strategies.

Establishing a robust radioligand therapy program: A practical approach for North American centers.

Radioligand therapy (RLT) is a targeted approach to treating cancer that has been shown to be safe and effective in a variety of disease states, including gastroenteropancreatic neuroendocrine tumors, lymphoma, and most recently, advanced prostate cancer. In the United States, patient access to this therapy is currently variable. Implementation of new RLT programs and expansion of existing programs are needed to broaden patient access to and standardize the delivery of RLT, especially as new therapies are introduced into clinical practice. Drawing from experience in establishing RLT programs in different settings, we have developed practical recommendations for building and implementing a robust RLT program. In this review, we present our recommendations for minimal requirements and optimal requirements, as well as system considerations, and special issues associated with implementing an RLT program in North American centers.

Essentials of Theranostics: A Guide for Physicians and Medical Physicists.

Radiopharmaceutical therapies (RPTs) are gaining increased interest with the recent emergence of novel safe and effective theranostic agents, improving outcomes for thousands of patients. The term theranostics refers to the use of diagnostic and therapeutic agents that share the same molecular target; a major step toward precision medicine, especially for oncologic applications. The authors dissect the fundamentals of theranostics in nuclear medicine. First, they explain the radioactive decay schemes and the characteristics of emitted electromagnetic radiation used for imaging, as well as particles used for therapeutic purposes, followed by the interaction of the different types of radiation with tissue. These concepts directly apply to clinical RPTs and play a major role in the efficacy and toxicity profile of different radiopharmaceutical agents. Personalized dosimetry is a powerful tool that can help estimate patient-specific absorbed doses, in tumors as well as normal organs. Dosimetry in RPT is an area of active investigation, as most of what we know about the relationship between delivered dose and tissue damage is extrapolated from external-beam radiation therapy; more research is needed to understand this relationship as it pertains to RPTs. Tumor heterogeneity is increasingly recognized as an important prognostic factor. Novel molecular imaging agents, often in combination with fluorine 18-fluorodeoxyglucose, are crucial for assessment of target expression in the tumor and potential hypermetabolic disease that may lack the molecular target expression. ©RSNA, 2023 Test Your Knowledge questions are available in the supplemental material.

The Improvement of Patient Centering in Computed Tomography Through a Technologist-Focused Education Initiative.

Proper patient centering is fundamental to the operation of CT. Misalignment of the patient is known to have a negative impact on image quality and dose. The purpose of this study was to improve patient centering in CT and examine the efficacy of several educational methods that could be implemented at any clinical site. The IRB determined the study was not human subjects research, and oversight was waived. Three interventions were examined. The first intervention involved a discussion on patient centering at a staff meeting. As the second intervention, an educational presentation was developed and delivered to CT technologists addressing the physics behind the importance of patient centering in CT. As the third intervention, individual technologist centering performance reviews were conducted by the modality supervisor. Clinical scan data was collected for each study period via a cloud-based software to examine the efficacy of each intervention in terms of lateral and vertical offset. The mean vertical offset of the baseline data was -1.97 cm. After the staff meeting, the mean vertical offset decreased to -1.60 cm (p < 0.001). Following the educational presentation, the mean vertical offset decreased to -1.14 cm (p < 0.001). After the technologist performance reviews, the mean vertical offset decreased to -0.86 cm (p < 0.001). This research examined a quality improvement initiative to improve patient centering at our institution which focused on communication and education. Through this initiative, the mean vertical positioning error decreased, the percentage of exams within 0-1 cm of isocenter increased, and the percentage of exams misaligned by greater than 3 cm decreased. This work has shown that patient centering can be improved with education.